| Dr Kuliakanda M Chengappa, MD | |
|
201 Stevens Mill Rd, Goldsboro, NC 27530-1056 | |
| (919) 731-3420 | |
| Not Available |
| Full Name | Dr Kuliakanda M Chengappa |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 51 Years |
| Location | 201 Stevens Mill Rd, Goldsboro, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376558825 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 21755 (North Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Josephs Com Support Services Inc | 0749579811 | 2 |
| Waynesboro Family Clinic | 3274445903 | 9 |
| Goldsboro Counseling Center Pa | 5890747885 | 3 |
News Archive
Eating a Mediterranean diet could decrease the chances an overweight person will experience regular pain, new research suggests.
Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million (USD 3.5 million) first seed funding round with a consortium of business angels and Belgian investment funds. EUR 1.6 million is from the European Regional Development Fund and the Walloon Region in Belgium via the Retech program for Research and Technology. It will be used to bring the company's lead product Ir-CPI into pre-clinical development over the next 18 months.
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the Opioid Growth Factor (OGF, [Met5]-enkephalin) and its receptor, OGFr, a clinically important system with potent antitumor properties, has controlled entry from the cytoplasm to the nucleus. The nucleocytoplasmic passage of OGF-OGFr is critical to cell proliferation and suggests that there are hierarchical levels of nuclear import.
› Verified 7 days ago
| Entity Name | Waynesboro Family Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760417570 PECOS PAC ID: 3274445903 Enrollment ID: O20031103000145 |
News Archive
Eating a Mediterranean diet could decrease the chances an overweight person will experience regular pain, new research suggests.
Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million (USD 3.5 million) first seed funding round with a consortium of business angels and Belgian investment funds. EUR 1.6 million is from the European Regional Development Fund and the Walloon Region in Belgium via the Retech program for Research and Technology. It will be used to bring the company's lead product Ir-CPI into pre-clinical development over the next 18 months.
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the Opioid Growth Factor (OGF, [Met5]-enkephalin) and its receptor, OGFr, a clinically important system with potent antitumor properties, has controlled entry from the cytoplasm to the nucleus. The nucleocytoplasmic passage of OGF-OGFr is critical to cell proliferation and suggests that there are hierarchical levels of nuclear import.
› Verified 7 days ago
| Entity Name | Goldsboro Counseling Center Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881651347 PECOS PAC ID: 5890747885 Enrollment ID: O20051207000150 |
News Archive
Eating a Mediterranean diet could decrease the chances an overweight person will experience regular pain, new research suggests.
Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million (USD 3.5 million) first seed funding round with a consortium of business angels and Belgian investment funds. EUR 1.6 million is from the European Regional Development Fund and the Walloon Region in Belgium via the Retech program for Research and Technology. It will be used to bring the company's lead product Ir-CPI into pre-clinical development over the next 18 months.
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the Opioid Growth Factor (OGF, [Met5]-enkephalin) and its receptor, OGFr, a clinically important system with potent antitumor properties, has controlled entry from the cytoplasm to the nucleus. The nucleocytoplasmic passage of OGF-OGFr is critical to cell proliferation and suggests that there are hierarchical levels of nuclear import.
› Verified 7 days ago
| Entity Name | Josephs Com Support Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215120720 PECOS PAC ID: 0749579811 Enrollment ID: O20160512000684 |
News Archive
Eating a Mediterranean diet could decrease the chances an overweight person will experience regular pain, new research suggests.
Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million (USD 3.5 million) first seed funding round with a consortium of business angels and Belgian investment funds. EUR 1.6 million is from the European Regional Development Fund and the Walloon Region in Belgium via the Retech program for Research and Technology. It will be used to bring the company's lead product Ir-CPI into pre-clinical development over the next 18 months.
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the Opioid Growth Factor (OGF, [Met5]-enkephalin) and its receptor, OGFr, a clinically important system with potent antitumor properties, has controlled entry from the cytoplasm to the nucleus. The nucleocytoplasmic passage of OGF-OGFr is critical to cell proliferation and suggests that there are hierarchical levels of nuclear import.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kuliakanda M Chengappa, MD 2509 Bradford Pl, Goldsboro, NC 27530-8152 Ph: (919) 735-2342 | Dr Kuliakanda M Chengappa, MD 201 Stevens Mill Rd, Goldsboro, NC 27530-1056 Ph: (919) 731-3420 |
News Archive
Eating a Mediterranean diet could decrease the chances an overweight person will experience regular pain, new research suggests.
Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million (USD 3.5 million) first seed funding round with a consortium of business angels and Belgian investment funds. EUR 1.6 million is from the European Regional Development Fund and the Walloon Region in Belgium via the Retech program for Research and Technology. It will be used to bring the company's lead product Ir-CPI into pre-clinical development over the next 18 months.
Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.
Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the Opioid Growth Factor (OGF, [Met5]-enkephalin) and its receptor, OGFr, a clinically important system with potent antitumor properties, has controlled entry from the cytoplasm to the nucleus. The nucleocytoplasmic passage of OGF-OGFr is critical to cell proliferation and suggests that there are hierarchical levels of nuclear import.
› Verified 7 days ago
Dr. Stephanie E Page, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 201 Stevens Mill Rd, Goldsboro, NC 27530 Phone: 919-731-3420 | |
Dr. Zahid Rauf, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1706 Wayne Memorial Dr, Goldsboro, NC 27534 Phone: 919-734-6676 Fax: 919-734-9050 | |
Jennifer A. Quinn, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: Cherry Hospital, 1401 West Ash Street, Goldsboro, NC 27530 Phone: 919-731-3206 | |
Teresa Tracy, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 817 Mill Rd, Goldsboro, NC 27534 Phone: 913-980-5370 | |
Ramaswamy Vellore Sriraman, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1706 Wayne Memorial Dr, Goldsboro, NC 27534 Phone: 919-734-6676 Fax: 919-734-9050 | |
Raye Mimi Zhu, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1401 W Ash St, Goldsboro, NC 27530 Phone: 919-947-7000 | |
Dr. Ralph Roger Berg Jr., M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1503 Wayne Memorial Dr, Suite H, Goldsboro, NC 27534 Phone: 919-330-4367 Fax: 919-330-4375 |